An innovative device designed to identify infection in dialysis patients has completed a successful pilot clinical investigation following a funding award from Health Innovation Manchester.

Manchester-based med-tech company Microbiosensor, secured £50,000 from Health Innovation Manchester in 2016 to pilot their PD Safe device in Manchester.

PD Safe is aimed at patients with kidney failure who are being treated using peritoneal dialysis therapy (PD). The device acts as an early warning system for peritonitis, an infection that can prove fatal if left untreated.

PD is the lowest cost and least lifestyle compromising form of renal dialysis available in the UK, however less than 10 per cent of patients on renal replacement therapy are on PD, with an average therapy duration of only five years.

Recurrent infections are a major cause of failure of PD and current best practice relies on a patient identifying possible symptoms of infection — abdominal pain, fever and visually checking a clear plastic waste bag for signs of cloudiness in their PD waste.

However, as the symptoms are not specific and not detectable until an infection has become well-established, patients can find making a judgement stressful and difficult – leading to a delay in time to diagnosis and treatment.

The PD Safe aims to overcome this issue by plugging into existing PD waste fluid tubing and flagging an emerging infection before symptoms present via a simple colour change in a readout window.

Following the funding award, Microbiosensor have completed a successful pilot clinical investigation of the PD Safe device at the Manchester Royal Infirmary renal centre.

The device successfully acted as an early warning system for infection, detecting bacteria within samples from patients, including one who was admitted to A&E within a few days as they went on to develop peritonitis.

Ben Bridgewater, Chief Executive of Health Innovation Manchester, said: “The PD Safe device is an excellent example how Health Innovation Manchester can support med-tech devices and companies in their journey to market.

“The successful pilot clinical investigation in Greater Manchester marks a great leap forward in the project which has the potential to meet the needs of local people and patients.

“It is vital that products such as the PD Safe are given support in order to improve people’s quality of life and Health Innovation Manchester is uniquely placed to champion these innovations and connect researchers, academics, business and the NHS in Greater Manchester.”

Gordon Barker, CEO of Microbiosensor, said: “The funding from Health Innovation Manchester helped Microbiosensor improve its understanding of clinical trial management at a major NHS Trust and strengthen the design of a subsequent larger study at Manchester Royal Infirmary.

“It has made a significant contribution to Microbiosensor efforts to bring its novel medical device technology to market.”

Microbiosensor has also secured a £1.4million investment from the Northern Powerhouse Investment Fund (managed by Maven Capital Partners) and the Greater Manchester and Cheshire Fund (managed by Catapult Ventures) to support the company through its final product development stages.